Going LIVE Today at 5pm: The EV Gold Rush Special Event
Here is the latest financial fact sheet of CIPLA. For more details, see the CIPLA quarterly results and CIPLA share price and chart. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | -0.3 |
No. of shares | m | 806.81 |
1 Week | % | 5.9 |
1 Month | % | -2.4 |
1 Year | % | 7.9 |
52 week H/L | Rs | 1,083.2/850.0 |
No. of Mths Year Ending |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
5-Yr Chart Click to enlarge
|
---|
CIPLA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 622 | 663 | 678 | 586 | 879 | |
Low | Rs | 458 | 479 | 484 | 357 | 411 | |
Sales per share (Unadj.) | Rs | 176.0 | 187.5 | 203.1 | 212.5 | 237.6 | |
Earnings per share (Unadj.) | Rs | 13.0 | 17.6 | 18.7 | 19.2 | 29.8 | |
Diluted earnings per share | Rs | 12.9 | 17.6 | 18.7 | 19.2 | 29.8 | |
Cash flow per share (Unadj.) | Rs | 29.4 | 34.1 | 35.2 | 33.8 | 43.0 | |
Dividends per share (Unadj.) | Rs | 2.00 | 3.00 | 3.00 | 4.00 | 5.00 | |
Adj. dividends per share | Rs | 1.99 | 2.99 | 3.00 | 4.00 | 5.00 | |
Avg Dividend yield | % | 0.4 | 0.5 | 0.5 | 0.8 | 0.8 | |
Book value per share (Unadj.) | Rs | 155.1 | 175.9 | 185.6 | 194.9 | 226.7 | |
Adj. book value per share | Rs | 154.7 | 175.5 | 185.4 | 194.7 | 226.6 | |
Shares outstanding (eoy) | m | 804.51 | 805.12 | 805.70 | 806.24 | 806.46 | |
Price / Sales ratio | x | 3.1 | 3.0 | 2.9 | 2.2 | 2.7 | |
Avg P/E ratio | x | 41.7 | 32.4 | 31.0 | 24.6 | 21.6 | |
P/CF ratio (eoy) | x | 18.4 | 16.8 | 16.5 | 14.0 | 15.0 | |
Price / Book Value ratio | x | 3.5 | 3.2 | 3.1 | 2.4 | 2.8 | |
Dividend payout | % | 15.4 | 17.0 | 16.0 | 20.8 | 16.8 | |
Avg Mkt Cap | Rs m | 434,516 | 459,723 | 468,032 | 379,858 | 519,826 | |
Total wages/salary | Rs m | 26,338 | 26,901 | 28,565 | 30,270 | 32,518 |
CIPLA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 141,583 | 150,922 | 163,624 | 171,320 | 191,596 | |
Other income | Rs m | 2,287 | 3,577 | 4,766 | 3,694 | 2,698 | |
Total revenues | Rs m | 143,870 | 154,498 | 168,390 | 175,014 | 194,294 | |
Gross profit | Rs m | 24,758 | 27,489 | 30,973 | 31,808 | 42,487 | |
Depreciation | Rs m | 13,229 | 13,228 | 13,263 | 11,747 | 10,677 | |
Interest | Rs m | 1,594 | 1,142 | 1,684 | 1,974 | 1,607 | |
Profit before tax | Rs m | 12,222 | 16,695 | 20,791 | 21,782 | 32,901 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 1,798 | 2,501 | 5,695 | 6,312 | 8,888 | |
Profit after tax | Rs m | 10,424 | 14,194 | 15,096 | 15,470 | 24,013 | |
Gross profit margin | % | 17.5 | 18.2 | 18.9 | 18.6 | 22.2 | |
Effective tax rate | % | 14.7 | 15.0 | 27.4 | 29.0 | 27.0 | |
Net profit margin | % | 7.4 | 9.4 | 9.2 | 9.0 | 12.5 |
CIPLA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 88,036 | 108,141 | 124,266 | 117,062 | 132,095 | |
Current liabilities | Rs m | 33,889 | 38,322 | 37,715 | 43,931 | 45,916 | |
Net working cap to sales | % | 38.2 | 46.3 | 52.9 | 42.7 | 45.0 | |
Current ratio | x | 2.6 | 2.8 | 3.3 | 2.7 | 2.9 | |
Inventory Days | Days | 45 | 49 | 72 | 50 | 68 | |
Debtors Days | Days | 7 | 8 | 9 | 8 | 7 | |
Net fixed assets | Rs m | 120,822 | 118,588 | 113,353 | 117,166 | 116,277 | |
Share capital | Rs m | 1,609 | 1,610 | 1,611 | 1,613 | 1,613 | |
"Free" reserves | Rs m | 123,207 | 140,019 | 147,941 | 155,487 | 181,232 | |
Net worth | Rs m | 124,816 | 141,629 | 149,552 | 157,100 | 182,844 | |
Long term debt | Rs m | 36,454 | 36,621 | 38,301 | 23,693 | 12,028 | |
Total assets | Rs m | 208,858 | 226,729 | 237,619 | 234,228 | 248,372 | |
Interest coverage | x | 8.7 | 15.6 | 13.3 | 12.0 | 21.5 | |
Debt to equity ratio | x | 0.3 | 0.3 | 0.3 | 0.2 | 0.1 | |
Sales to assets ratio | x | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | |
Return on assets | % | 5.8 | 6.8 | 7.1 | 7.4 | 10.3 | |
Return on equity | % | 8.4 | 10.0 | 10.1 | 9.8 | 13.1 | |
Return on capital | % | 8.6 | 10.0 | 12.0 | 13.1 | 17.7 | |
Exports to sales | % | 35.3 | 33.1 | 33.9 | 32.2 | 31.3 | |
Imports to sales | % | 6.8 | 13.9 | 11.6 | 3.4 | 10.9 | |
Exports (fob) | Rs m | 50,050 | 49,883 | 55,419 | 55,175 | 59,951 | |
Imports (cif) | Rs m | 9,616 | 21,033 | 19,041 | 5,903 | 20,911 | |
Fx inflow | Rs m | 51,066 | 51,691 | 57,410 | 56,036 | 68,051 | |
Fx outflow | Rs m | 17,678 | 21,033 | 19,041 | 5,903 | 20,911 | |
Net fx | Rs m | 33,388 | 30,658 | 38,368 | 50,133 | 47,140 |
CIPLA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 23,818 | 14,628 | 16,911 | 30,685 | 37,552 | |
From Investments | Rs m | -13,102 | -8,540 | -16,687 | 1,040 | -23,872 | |
From Financial Activity | Rs m | -13,257 | -3,855 | -3,487 | -29,488 | -13,299 | |
Net Cashflow | Rs m | -2,478 | 2,431 | -3,451 | 2,340 | 509 |
Share Holding
Shareholding as on Mar 2022
|
Company Information
|
CHM: Y K Hamied | COMP SEC: Rajendra Chopra | YEAR OF INC: 1935 | BSE CODE: 500087 | FV (Rs): 2 | DIV YIELD (%): 0.5 |
More Pharmaceuticals Company Fact Sheets: SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES LUPIN AUROBINDO PHARMA
Compare CIPLA With: SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES LUPIN AUROBINDO PHARMA
Asian share markets are lower today as persistent worries about inflation and rising interest rates dogged the global economic outlook and fresh selling in technology stocks weighed on Chinese markets.
The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
As the new variant of Covid-19 emerges, keep an eye on these stocks.
These companies are likely to benefit the most from Covid-19 vaccines.
For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
More Views on NewsWe are just two months into 2022 and several penny stocks that we track have already surged 5x.
Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.
A step-by-step method to pick the best penny stocks for the long term.
These penny stocks can become future multibaggers. Watch out for them.
Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?
More